LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Effect of Dexmedetomidine on Incidence of Hypertension Following Repair of Coarctation of the Aorta.

    Abarintos, Hope Mae L / Kapuscinski, Christine A / Wheaton, Taylor / Stauber, Sierra D / Swartz, Michael F / Grossman, Madeline / Masri, Sarah / Hutchinson, David J

    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

    2024  Volume 29, Issue 2, Page(s) 144–150

    Abstract: Objective: Recent literature suggests a potential role for dexmedetomidine in reducing the incidence and severity of hypertension following repair of coarctation of the aorta (CoA). The primary aim of this study was to assess the association between ... ...

    Abstract Objective: Recent literature suggests a potential role for dexmedetomidine in reducing the incidence and severity of hypertension following repair of coarctation of the aorta (CoA). The primary aim of this study was to assess the association between dexmedetomidine use and the incidence of hypertension following repair of CoA in pediatric patients.
    Methods: This was a single-center, retrospective cohort study in patients younger than 19 years who underwent surgical repair of CoA between January 1, 2016, and September 30, 2021. Patients were divided into 2 groups: dexmedetomidine initiation within the first 3 hours after surgery or no dexmedetomidine. The primary outcome was incidence of hypertension within the first 4 to 24 hours after repair. Secondary outcomes included the incidence of hypotension and bradycardia.
    Results: A total of 80 patients were included, 25 (31.25%) received dexmedetomidine. Median age at the time of procedure was 26 days (IQR, 13-241) in the dexmedetomidine group and 14 days (IQR, 8-53) in the no dexmedetomidine group (p = 0.014). The primary outcome of hypertension was met in 7 patients (28%) in the dexmedetomidine group and 12 patients (21.8%) in the no dexmedetomidine group, p = 0.547. The only variable found to be associated with the incidence of hypertension was age greater than 30 days at the time of procedure. More patients who received dexmedetomidine experienced bradycardia. There was no difference in the incidence of hypotension.
    Conclusions: There was no association between the use of dexmedetomidine and the incidence of -hypertension following repair of CoA in pediatric patients.
    Language English
    Publishing date 2024-04-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3028543-4
    ISSN 1551-6776
    ISSN 1551-6776
    DOI 10.5863/1551-6776-29.2.144
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature.

    Masri, Sarah / Kenney, Anna E / Scigliano, Don / Juba, Katherine M

    Journal of pain & palliative care pharmacotherapy

    2022  Volume 37, Issue 2, Page(s) 178–183

    Abstract: Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety. An uncommon adverse effect of GBP is ... ...

    Abstract Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety. An uncommon adverse effect of GBP is urinary incontinence (UI). We report the case of a 61-year-old male with metastatic non-small cell lung cancer who developed probable overflow UI while receiving 1200 mg/day of GBP for chemotherapy-induced peripheral neuropathy. The patient self-tapered GBP to 600 mg/day which resolved the overflow UI, but resulted in poorly controlled bilateral foot pain. The palliative care physician rotated the patient to pregabalin 150 mg/day and his bilateral foot pain improved after his regimen was titrated to 200 mg/day. The patient did not experience overflow UI while taking pregabalin despite the similar pharmacology and comparable doses to GBP. We believe this is the first case report to describe subsequent achievement of pain control by substituting pregabalin without recurrence of UI. Healthcare professionals should consider GBP as a potential cause when evaluating patients presenting with new onset overflow UI.
    MeSH term(s) Male ; Humans ; Middle Aged ; Gabapentin/adverse effects ; Pregabalin/adverse effects ; Carcinoma, Non-Small-Cell Lung/chemically induced ; gamma-Aminobutyric Acid/adverse effects ; Amines/adverse effects ; Cyclohexanecarboxylic Acids/adverse effects ; Lung Neoplasms/chemically induced ; Neuralgia ; Urinary Incontinence/chemically induced ; Analgesics/adverse effects
    Chemical Substances Gabapentin (6CW7F3G59X) ; Pregabalin (55JG375S6M) ; gamma-Aminobutyric Acid (56-12-2) ; Amines ; Cyclohexanecarboxylic Acids ; Analgesics
    Language English
    Publishing date 2022-12-20
    Publishing country England
    Document type Review ; Case Reports ; Journal Article
    ZDB-ID 2078852-6
    ISSN 1536-0539 ; 1536-0288
    ISSN (online) 1536-0539
    ISSN 1536-0288
    DOI 10.1080/15360288.2022.2160042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2463: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Management of breast cancer patients with

    Abdel-Razeq, Hikmat / Abbasi, Salah / Abdeen, Ghadeer / Abdulelah, Hazem / Debs, Jamil / Al Masri, Sarah / Aljadayeh, Majdi H / Awidi, Abdalla

    Hospital practice (1995)

    2023  Volume 51, Issue 4, Page(s) 184–191

    Abstract: Background: This paper explores and discusses local challenges oncologists face for diagnosing and managing breast cancer patients with BRCA gene mutations in Jordan.: Methods: A task force involving key opinion leaders, experts in the management of ... ...

    Abstract Background: This paper explores and discusses local challenges oncologists face for diagnosing and managing breast cancer patients with BRCA gene mutations in Jordan.
    Methods: A task force involving key opinion leaders, experts in the management of breast cancer, and stakeholders in healthcare systems where genetic testing is available in Jordan discussed current evidence and local real-life practice. The task force then formulated recommendations to achieve better patient outcomes and satisfaction based on evidence-based medicine and their clinical experience in BRCA-mutated breast cancer management.
    Results and conclusion: Eligibility of patients for genetic testing, physician acceptance and willingness to integrate genetic testing into routine practice is encouraging but remains restricted by testing availability and financial coverage. Until more data is available, genetic testing should be targeted for breast cancer patients based on tumor subtypes, as well as family and personal history of cancer, as per international guidelines. Whenever possible, genetic testing should aim to detect all actionable genes through a multigene panel including BRCA1/2. Major challenges faced in clinical practice in Jordan include fear of genetic discrimination and social stigmatization, as well as hesitancy toward risk-reducing surgery. Pre-testing counseling is therefore critical to promote acceptance of genetic testing. Since geneticists are in short supply in Jordan, genetic counseling can be offered through a specially trained genetic counselor or through a hybrid system that includes oncologist-based counselling. In addition to cancer prevention, germline genetic testing may assist in the selection of specific anti-cancer therapy, such as PARP inhibitors, in patients with BRCA1/2 mutation. Nationwide initiatives are also needed to ensure access to PARP inhibition therapy and provide financial coverage for genetic screening, mastectomies and reconstructive surgery across Jordan.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; BRCA1 Protein/genetics ; Mutation ; BRCA2 Protein/genetics ; Jordan
    Chemical Substances BRCA1 protein, human ; BRCA1 Protein ; BRCA2 protein, human ; BRCA2 Protein
    Language English
    Publishing date 2023-11-16
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2570453-9
    ISSN 2377-1003 ; 2154-8331 ; 8750-2836
    ISSN (online) 2377-1003
    ISSN 2154-8331 ; 8750-2836
    DOI 10.1080/21548331.2023.2266019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 890: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.

    Ramadan, Wijdan H / Al Masri, Sarah / Rizk, John

    The clinical respiratory journal

    2019  Volume 13, Issue 11, Page(s) 663–673

    Abstract: Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is predicted to be one of the leading causes of death worldwide. Pharmacologic treatment options of COPD are bronchodilators, using either long-acting β2-agonists (LABAs), ... ...

    Abstract Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that is predicted to be one of the leading causes of death worldwide. Pharmacologic treatment options of COPD are bronchodilators, using either long-acting β2-agonists (LABAs), or long-acting muscarinic antagonists (LAMAs), or a combination of two. Anoro Ellipta (umeclidinium + vilanterol) dry powder inhaler, a fixed-dose combination of LAMA and LABA, was Food and Drug Administration (FDA) approved in 2013 for COPD. The objective of this study is to evaluate the efficacy and safety of once daily umeclidinium/vilanterol (62.5 mcg/25 mcg) in COPD patients, focusing on pharmacodynamic and pharmacokinetic characteristics, efficacy and safety in clinical studies and cost. Literature search was done through PubMed (2004-2017) using the terms umeclidinium, vilanterol, COPD, LABA and LAMA. Recent and significant clinical trials about the monocomponents and their combination were identified, in addition to reviews, guidelines for COPD, data from manufacturer and FDA product labels. The search was limited to English language studies on human subjects. Clinical data published on the combination of umeclidinium/vilanterol in patients with COPD have shown greater improvements in lung function compared to monotherapies. However, further studies comparing umeclidinium/vilanterol FDC (ANORO) to other LABA/LAMA combinations are needed.
    MeSH term(s) Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adrenergic beta-2 Receptor Agonists/pharmacology ; Benzyl Alcohols/administration & dosage ; Benzyl Alcohols/adverse effects ; Benzyl Alcohols/pharmacokinetics ; Benzyl Alcohols/pharmacology ; Bronchodilator Agents/administration & dosage ; Bronchodilator Agents/pharmacology ; Chlorobenzenes/administration & dosage ; Chlorobenzenes/adverse effects ; Chlorobenzenes/pharmacokinetics ; Chlorobenzenes/pharmacology ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Dry Powder Inhalers ; Forced Expiratory Volume/drug effects ; Humans ; Muscarinic Antagonists/pharmacokinetics ; Muscarinic Antagonists/pharmacology ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/mortality ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinuclidines/administration & dosage ; Quinuclidines/adverse effects ; Quinuclidines/pharmacokinetics ; Quinuclidines/pharmacology ; Randomized Controlled Trials as Topic ; Respiratory Function Tests/methods
    Chemical Substances Adrenergic beta-2 Receptor Agonists ; Benzyl Alcohols ; Bronchodilator Agents ; Chlorobenzenes ; GSK573719 ; Muscarinic Antagonists ; Quinuclidines ; vilanterol (028LZY775B)
    Language English
    Publishing date 2019-09-02
    Publishing country England
    Document type Comparative Study ; Journal Article ; Systematic Review
    ZDB-ID 2442214-9
    ISSN 1752-699X ; 1752-6981
    ISSN (online) 1752-699X
    ISSN 1752-6981
    DOI 10.1111/crj.13073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top